Key clinical point: Tralokinumab-mediated inhibition of interleukin (IL)-13 improved epidermal pathology and reduced the expression of key atopic dermatitis (AD) biomarkers in the serum of patients with moderate to severe AD.
Major finding: At week 16, tralokinumab vs placebo led to a significantly greater decrease from baseline in serum levels of type 2 biomarkers (CCL17/TARC, periostin, immunoglobulin E, and IL-22; all P < .05), a greater mean percentage change in the Eczema Area Severity Index score (−55.6 vs −36.7), and improved expression of genes dysregulated in AD (46.6% vs 16.4%; P < .001).
Study details: This study involved the collection of blood samples from 802 patients with moderate to severe AD randomized in the ECZTRA 1 and ECZTEND trials, followed by the selection of a subset of 299 patients with relevant samples available who had received tralokinumab (n = 223) or placebo (n = 76).
Disclosures: LEO Pharma A/S funded both ECZTRA 1 and the ongoing ECZTEND trial. Six authors declared being employees or shareholders of LEO Pharma. Several authors declared receiving research grants from or having other ties with various sources, including LEO Pharma.
Source: Guttman-Yassky E, Kabashima K, Staumont-Salle D, et al. Targeting IL-13 with tralokinumab normalizes type 2 inflammation in atopic dermatitis both early and at 2 years. Allergy. 2024 (Apr 2). doi: 10.1111/all.16108 Source